Skip to main content
Clinical Trials/KCT0006378
KCT0006378
Withdrawn
未知

MR guided Pre-operative RT in Gastric Cancer

Washington University School of Medicine0 sites18 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Washington University School of Medicine
Enrollment
18
Status
Withdrawn
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional Study
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\.Newly diagnosed histologically or cytologically gastric adenocarcinoma. (Siewert III acceptable: the bulk of tumor should be in stomach; gastric tumors with extension to the gastroesophageal junction are permitted.) Patients with T1\-T2N1 and T3Nx disease are eligible (stage I\-III). Patients with T2N0, N3, T4, M1, or T1N0 disease are not eligible.
  • 2\.T\-stage defined by EUS. Must have had CT of the chest/abdomen/pelvis with oral and IV contrast.
  • 3\.Medically eligible to receive CAPOX chemotherapy.
  • 4\.At least 18 years of age (per US calculation of age).
  • 5\.ECOG performance status \= 2 (see Appendix A)
  • 6\.Normal bone marrow and organ function as defined below:
  • a.Absolute neutrophil count \= 1,500 cells/mm3
  • b.Platelets \= 100,000 cells/mm3
  • c.Hemoglobin \> 9 g/dL
  • d.Creatinine clearance \> 50 mL/min

Exclusion Criteria

  • 1\.Prior surgery, radiation, or chemotherapy for gastric or esophageal cancer.
  • 2\.Prior surgery to the esophagus or stomach.
  • 3\.Siewert I\-II GE junction tumor.
  • 4\.Any active malignancy within 2 years that may alter the course of gastric cancer. (Apparently cured localized malignancy or advanced, but indolent malignancy with significantly more favorable prognosis are allowed).
  • 5\.Currently receiving any other investigational agents.
  • 6\.Metastatic disease, including gross peritoneal carcinoma.
  • 7\.Presence of ascites.
  • 8\.A history of allergic reactions attributed to compounds of similar chemical or biologic composition to capecitabine, oxaliplatin, or other agents used in the study.
  • 9\.Contraindications to MRI (e.g., non\-compatible implantable device or metallic foreign bodies).
  • 10\.Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, diabetes, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia.

Outcomes

Primary Outcomes

Not specified

Similar Trials